Unknown

Dataset Information

0

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.


ABSTRACT: INTRODUCTION:3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy. METHODS:We conducted a randomized double-blind placebo-controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for???3 months. The primary efficacy endpoint was >30% deterioration in triple timed up-and-go (3TUG) times during tapered drug withdrawal. The secondary endpoint was self-assessment of LEM-related weakness (W-SAS). RESULTS:Thirty-two participants were randomized to continuous 3,4-DAP or placebo groups. None of the 14 participants who received continuous 3,4-DAP had?>?30% deterioration in 3TUG time versus 72% of the 18 who tapered to placebo (P?

SUBMITTER: Sanders DB 

PROVIDER: S-EPMC5900968 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Introduction</h4>3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy.<h4>Methods</h4>We conducted a randomized double-blind placebo-controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in triple timed up-and-go (3TUG) times during tapered drug withdrawal. The secondary endp  ...[more]

Similar Datasets

| S-EPMC5613184 | biostudies-literature
| S-EPMC7357813 | biostudies-literature
| S-EPMC9868566 | biostudies-literature
| S-EPMC5521354 | biostudies-other
| S-EPMC7324357 | biostudies-literature
| S-EPMC4335987 | biostudies-literature
| S-EPMC7080283 | biostudies-literature
| S-EPMC4157148 | biostudies-literature
| S-EPMC7318278 | biostudies-literature
| S-EPMC9164507 | biostudies-literature